Bernard-Marty C, Cardoso F, Piccart M J
Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 215, 1000, Brussels, Belgium.
Eur J Cancer. 2003 Sep;39(14):1978-89. doi: 10.1016/s0959-8049(03)00538-0.
Taxanes are currently introduced early in the treatment of patients with metastatic breast cancer (MBC), both as single agents and in combination with anthracyclines. Two different patient populations exist: those with no or minimal prior anthracycline exposure and those who have failed previous anthracyclines. The data generated through phase III trials in first-line MBC therapy will be reviewed and their interpretation for routine clinical practice (use versus abuse) will be discussed. Ways of improving taxane-based treatment tailoring both in the pre- and postgenomic eras will be addressed.
紫杉烷类目前在转移性乳腺癌（MBC）患者的治疗早期就被引入，既作为单一药物，也与蒽环类药物联合使用。存在两种不同的患者群体：那些之前未接触过或极少接触过蒽环类药物的患者，以及那些之前使用蒽环类药物治疗失败的患者。将回顾在一线MBC治疗中通过III期试验产生的数据，并讨论其在常规临床实践中的解读（合理使用与滥用）。还将探讨在基因组学时代之前和之后改善基于紫杉烷类治疗的个体化方法。
